Table 3 –

Longitudinal analysis of BMI and FEV₁

	Model 1 (PS only)	Model 2 (PS+PI)	Model 3 (PS+PI)
BMI	0.079 (0.051, 0.11) ‡	---	---
BMI Pancreatic status Interaction term	---	0.20 (0.195, 0.207)‡ 13.19 (10.36, 16.01)‡ −0.11 (−0.15, −0.08)‡	---
BMI in PI-CF BMI in PS-CF	---	---	0.20 (0.195, 0.207) ‡ 0.09 (0.055, 0.13) ‡
Female sex	1.07 (−1.45, 3.60)	−1.21 (−1.88, −0.53)‡	−1.21 (−1.88, −0.53)‡
Non-white race	−2.94 (−7.60, 1.72)	0.55 (−0.84, 1.95)	0.55 (−0.84, 1.95)
Hispanic/Latino Data missing1	0.99 (−2.54, 4.52) 1.54 (−4.32, 7.40)	−5.39 (−6.49, −4.30)‡ 0.25 (−1.42, 1.93)	−5.39 (−6.49, −4.30)‡ 0.25 (−1.42, 1.93)
Non-private insurance Data missing1	0.12 (−1.07, 1.30) 0.34 (−1.44, 2.11)	−0.84 (−1.12, −0.56)‡ −1.13 (−1.56, −0.70)‡	−0.84 (−1.12, −0.56)‡ −1.13 (−1.56, −0.70)‡
Pseudomonas Data missing1	−0.25 (−1.81, 1.30) 6.93 (−0.62, 14.47)	−2.16 (−2.56, −1.76)‡ −0.70 (−2.48, 1.08)	−2.16 (−2.56, −1.76)‡ −0.70 (−2.48, 1.08)
Burkholderia Data missing1	−6.21 (−10.55, −1.86)† −7.63 (−14.28, −0.97)*	−7.30 (−8.13, −6.47)‡ 1.62 (0.75, 2.50)‡	−7.30 (−8.13, −6.47)‡ 1.62 (0.75, 2.50)‡
Tobramycin	−1.29 (−2.62, 0.03)	0.80 (0.60, 1.01) ‡	0.80 (0.60, 1.01) ‡
HTS Data missing1	−0.88 (−1.95, 0.18) 4.20 (2.46, 5.93)‡	−3.73 (−3.95, −3.51)‡ 4.04 (3.71, 4.36)‡	−3.73 (−3.95, −3.51)‡ 4.04 (3.72, 4.36)‡
DNase	−1.57 (−2.74, −0.41)†	−1.00 (−1.33, −0.67)‡	−1.00 (−1.33, −0.67)‡

Results from the adjusted longitudinal regression analysis. Shown are effect estimates (β coefficients) for FEV1pp, with 95% confidence intervals (95%CI) in parentheses. Model 1: Main effect of BMI in the PS-CF cohort. Model 2: Analysis of the whole cohort (PS and PS) showing the main effects of BMI, pancreatic status (PI or PS), and their interaction (BMI*pancreatic status). Model 3: Main effect of BMI in each of the pancreatic status groups, accounting for the effect modification.

¹Variables with >10% missing data were assigned a “missing” category.

^*P<0.05,

^†P<0.01,

^‡P<0.001.